Knight Therapeutics Enters into Agreement for a $75 Million "Bought Deal" Private Placement of Special Warrants

MONTREAL, QUEBEC--(Marketwired - March 21, 2014) -

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Knight Therapeutics Inc. ("Knight" or the "Company") (TSX VENTURE:GUD) today announced that it has entered into a letter agreement with a syndicate of underwriters co-led by GMP Securities L.P. and Cormark Securities Inc. (collectively, the "Underwriters"), and including Bloom Burton & Co. as a selling group member, pursuant to which the Underwriters have agreed to purchase, on a private placement basis, 14,300,000 special warrants (the "Special Warrants") of the Company at a price of $5.25 per Special Warrant (the "Offering Price") for aggregate gross proceeds to Knight of $75,075,000 (the "Offering").

3487911 Canada Inc. or an affiliate thereof ("3487911"), an entity controlled by the Company's President and Chief Executive Officer, Jonathan Ross Goodman, has agreed to purchase in the aggregate 4,800,000 Special Warrants under the Offering (approximately $25 million) to maintain its current pro-rata ownership interest in the Company.

Each Special Warrant will be exercisable into one common share in the capital of Knight (the "Common Shares") for no additional consideration. The Special Warrants will be deemed to be exercised upon the earlier of: (i) a date that is no later than the fifth business day after the date of issuance of a receipt for a final prospectus qualifying the issuance of Common Shares underlying the Special Warrants; and (ii) four months and one day following the closing of the Offering. Knight has agreed to use its commercially reasonable efforts to file a prospectus qualifying the issuance of the Common Shares underlying the Special Warrants in all provinces of Canada where purchasers of Special Warrants are resident.

The Offering is expected to close on or about April 10, 2014 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange. The proceeds of the Offering will be used to fund Knight's future growth as well as for general corporate purposes.

Under the agreement, the Underwriters will be entitled to a cash commission equal to 5.0% of the gross proceeds from the Offering (other than from sales to 3487911).

When reflecting on Knight's first three weeks of operations, Jonathan Ross Goodman stated "In the first three weeks since Knight's birth, we have raised $150 million in two financing rounds at increasing valuations, and received from the U.S. FDA approval for Impavido^® for multiple forms of leishmaniasis along with a priority review voucher. In short, it has been an incredibly fun and successful first three weeks of existence."

The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Knight Therapeutics Inc.:

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. Knight Therapeutics' shares began trading on the TSX-V on March 3, 2014 under the symbol GUD. For more information about Knight Therapeutics, please visit the Company's web site at www.gud-knight.com or at www.sedar.com.

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the Company's final application for listing on the TSX Venture Exchange and can be found on SEDAR at www.sedar.com, which investors should consult for additional information. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.